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ABSTRACT 
Abnormal production and function of surfactants are associated with pulmonary diseases. Also, pulmonary infections alter 
surfactant metabolism. Due to lack of information on the levels of surfactants A (SP-A) and D (SP-D) in Nigerian 
tuberculosis (TB) patients, this study assessed these surfactants in both sputum and serum of drug sensitive- and multidrug 
resistant- TB patients using ELISA. The aim is to explore the diagnostic or therapeutic potential of SP-A and SP-D in TB 
patients. Also, to find out appropriate sample for the analyses of SP-A and SP-D in TB patients. 
The mean serum levels of SP-A and SP-D were not significantly reduced in MDR-TB (n=30) and DS-TB patients (n=30) 
compared with non-TB apparently healthy controls (n=30) (p > 0.05). Mean sputum levels of SP-A and SP-D were 
significantly reduced in DS-TB patients compared with the levels in MDR-TB patients (p < 0.05). These findings suggest 
that the sputum SP-D and SP-A levels but not serum SP-D and SP-A levels are useful indicators of the disease activity in 
pulmonary TB patients.  
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Résumé 
production anormale et la fonction d'agents tensio-actifs sont associés à des maladies pulmonaires. En outre, les infections 
pulmonaires modifier le métabolisme du surfactant. En raison du manque d'informations sur les niveaux d'agents de 
surface A (SP-A) et D (SP-D) in Nigerian la tuberculose (TB) patients, cette étude a évalué ces surfactants dans les 
expectorations et le sérum de la multirésistance et sensible-- patients atteints de tuberculose à l'aide d'ELISA. L'objectif est 
d'explorer les possibilités diagnostiques ou thérapeutiques de SP-A et SP-D dans les patients atteints de tuberculose. Aussi, 
nous avons voulu en savoir échantillon approprié pour l'analyse de SP-A et SP-D dans les patients atteints de tuberculose. 
Les niveaux sériques de SP-A et SP-D n'ont pas été significativement réduite dans la TB-MR (n =30) et DS-TB patients (n 
=30) par rapport aux non-contrôles apparemment en bonne santé (n =30) (p  > 0,05). Les niveaux d'expectorations de SP-A et 
SP-D ont été significativement réduits dans DS-tuberculeux par rapport aux niveaux de la multirésistance patients (p  < 
0,05). Ces résultats suggèrent que l'expectoration SP-D et SP-A mais pas la SP-D et SP-A sont des indicateurs utiles à 
l'activité de la maladie chez les patients atteints de tuberculose pulmonaire. 
Mots clés : Tuberculose, surfactants, le diagnostic, le Nigeria
 
INTRODUCTION 
Mycobacterium tuberculosis (M.tb) is a facultative 
intracellular pathogen that infects humans causing 
tuberculosis (1, 2). Inhalation of infectious aerosols 
is the common route of transmission and it is finally 
deposited in the terminal bronchioles and alveoli of 
the lungs (3). At this early stage of infection, 
interactions of M.tb with the innate immune 
environment of the lung have been proposed to 
determine the outcome and progression 
of M.tb infection (2). However, such interactions are  
 
 
incompletely known. One of the first interactions 
of M.tb in the lung is the binding is pulmonary 
surfactant molecules, which are multi-molecular 
complexes composed of lipids and proteins secreted 
by alveolar type II cells and Clara cells in distal 
bronchioles (4, 5).  
 
Four specific surfactant proteins have been 
identified viz: surfactant protein SP-A, SP-B, SP-C 
and SP-D. SP-B and SP-C have been characterized 
as hydrophobic polypeptides that enhance the 
adsorption of lipid to the surface of the alveoli (6). 
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On the other hand SP-A and SP-D are hydrophilic 
and participate in the innate host defense immune 
system. SP-D binds to macrophages and 
neutrophils and promotes phagocytosis and 
killing of bacteria, fungi, and viruses (7). SP-A and 
SP-D lines the lungs and are essential for 
pulmonary function by reducing surface tension (5-
7). SP-A and SP-D also play important roles in 
innate immune responses to a wide range of 
respiratory pathogens including M.tb (8-15). 
Additionally, it has been shown that pulmonary SP-
D contributes significantly to host control of 
infections by the parasitic helminth Nippostrongylus 
brasiliensis (16).  
 
Binding of pathogens by SP-A and SP-D trigger 
various immune responses, including opsonisation 
leading to enhanced phagocytosis and killing by 
recruited macrophages and neutrophils via 
oxidative mechanisms, aggregation of pathogens 
thereby hindering their entry into host cells, and 
direct microbicidal activities by increasing cellular 
membrane permeability (17). SPs also assist in the 
clearance of apoptotic cells and in modulating 
inflammation (18). The interaction of SPs with 
immune cells to initiate clearance mechanisms is 
mediated by SP's collagen region with a number of 
proposed receptor molecules on these cells (19).  
Considering the intricate relationship between SP-A 
and SP-D with innate immune cells necessary to 
control respiratory pathogens, the present study 
thus determined both serum and sputum levels of 
SP-A and SP-D in DS-TB and MDR-TB, which were 
not previously studied among Nigerian TB patients. 
MATERIALS AND METHODS 
A total of 90 participants were enrolled for this 
study. This comprised of thirty (30) multi-drug 
resistant TB (MDR-TB) patients, thirty (30) drug-
sensitive TB (DS-TB) patients and thirty (30) non-TB 
apparently healthy controls. MDR-TB patients had 
been previously diagnosed as being infected with 
isoniazid and rifampicin resistant strains of 
Mycobacterium tuberculosis (Mtb) using clinical 
history, Chest X-ray and GENE Xpert. These 
patients were admitted into the MDR-TB centre, 
University College Hospital (UCH) Ibadan, Nigeria 
for anti-TB treatment. DS-TB patients were 
recruited from the Medicine Out-patient Clinic, 
University College Hospital, Ibadan, Nigeria by a 
Consultant Chest Physician after confirmation with 
Microbiological test (sputum smear microscopy), 
chest X-ray and clinical history.  Five milliliters (5 
ml) of blood was drawn from the antecubital vein of 
each participant and dispensed into sterile plain 
sample tubes without anticoagulant. Blood was 
centrifuged at 1000g for 15mins and serum was 
obtained. Serum was stored at -20oC until analysis. 
Spot collection of sputum sample was carried out. 
Study participants were asked to rinse their mouth 
with water to reduce salivary contamination of 
sputum. Sputum produced was collected into 20ml 
sterile disposable polypropylene tubes and kept on 
ice from collection to arrival at the laboratory. 
Sputum sample was homogenized with an equal 
volume of phosphate buffered saline (PBS). 
Homogenate was centrifuged at 10,000g for 10 
minutes to remove cellular debris and mucus, and 
supernatant obtained was stored at -20oC until 
analysis. Enzyme Linked Immunosorbent Assay 
(ELISA) method was used for the determination of 
serum and sputum concentrations of surfactant-
associated protein A (SP-A) and Surfactant-




As shown in the Table, the mean serum levels of SP-
A were not significantly reduced in MDR-TB 
patients and DS-TB patients compared with control 
while the mean serum levels of SP-D were not 
significantly raised in MDR-TB patients and DS-TB 
patients compared with control. The mean sputum 
levels of SP-A was significantly reduced in DS-TB 
patients compared with MDR-TB patients and 
control while the mean sputum levels of SP-D were 
significantly raised in DS-TB patients and MDR-TB 
patients compared with control. Also, the mean 
sputum level of SP-D was significantly raised in 
MDR-TB patients compared with DS-TB patients. 
 
 
TABLE 1: COMPARISON OF MEAN LEVELS OF SPUTUM AND SERUM SP-A (NG/L) AND SP-D (PG/ML) IN MDR-TB, 
DS-TB AND CONTROL 
Variables MDR-TB DS-TB Control p' p'' p''' 
Serum SP-A 306.90±133.32 344.66±139.87 368.72±210.37 0.361 0.725 0.455 
Sputum SP-A 503.22±170.25 312.03±187.98 570.15±175.43 0.326 0.001* 0.007* 
Serum SP-D 1709.38±665.56 1701.31±596.96 1547.34±324.58 0.448 0.430 0.972 
Sputum SP-D 3596.45±636.45 2600.0±1085.04 1210.57±457.39 0.000* 0.000* 0.005* 
p' MDR-TB compared with control; p'' DS-TB compared with control; p''' MDR-TB compared with DS-TB 






Tuberculosis which claims at least 3 million lives 
annually is caused by M.tb (1, 2). The interaction 
between M.tb and the pulmonary lining represents 
the initial contact of the bacterium with the host 
immune system (1-3), thus the factors which affect 
phagocytosis of M.tb by host immune cells are 
important to our understanding of disease 
pathogenesis. Surfactant and its associated proteins, 
in conjunction with alveolar macrophages, are 
important components of the pulmonary alveoli. 
Surfactant proteins (SP-A, SP-B, SP-C, and SP-D) 
are enriched with a relatively unique phospholipid 
(dipalmitoylphosphatidylcholine) (3, 4). The main 
functions of surfactant are lowering surface tension 
at the air–liquid interface and thus preventing 
alveolar collapse at end-expiration, interacting with 
and subsequent killing of pathogens or preventing 
their dissemination and modulating immune 
responses (5-7).Two major surfactant associated 
proteins, surfactant protein A (SP-A) and surfactant 
protein D (SP-D), contain carbohydrate recognition 
domains (CRDs) (3-7).  
SP-A binds with lipopolysaccharides and 
peptidoglycan derived from K. pneumoniae, E. 
coli, P. aeruginosa and Legionella pneumophila, 
Staphylococcus aureus and Streptococcus pneumoniae 
as well as Mycobacterium avium, Mycobacterium 
tuberculosis and Mycoplasma pneumoniae which 
consequently result in agglutination, enhancement 
of pathogen uptake, and growth inhibition (8-15). 
The metabolism of SP-A in TB patients considered 
for this study might account for reduced levels of 
SP-A especially in the sputum which is a 
transmission medium for M.tb. This may be to 
agglutinate Mt.b in local environment. This 
hypothesis is supported by a previous study (21) 
which reported that human SP-A enhances the 
uptake of the virulent Erdman strain of M.tb by 
human monocyte-derived macrophages and human 
alveolar macrophages through direct interaction 
with the macrophages. The study thus concluded 
thatSP-A was reported to play a role in the 
pathogenesis of tuberculosis by enhancing the 
ability of M.tb to enter and survive within its local 
niche in the host. Another data suggested that SP-A 
has pleiotropic effects even at the low 
concentrations found in tuberculosis patients (22). 
SP-A was reported to augment inflammation in the 
presence of infection and inhibits inflammation in 
uninfected macrophages so as to protect 
uninvolved lung segments from the deleterious 
effects of inflammation (23). This further support 
reduced level of SP-A in TB patients as a result of 
continuous metabolism. 
SP-D is synthesized and secreted into the airspaces 
of the lung by the respiratory epithelium (4, 5). At 
the alveolar level, SP-D is constitutively synthesized 
and secreted by alveolar type II cells. More 
proximally in the lung, SP-D is secreted by a subset 
of bronchiolar epithelial cells, the non-ciliated Clara 
cells. Because SP-D is stored within the secretory 
granules of Clara cells (6, 9), it seems likely that SP-
D is subject to regulated secretion via granule 
exocytosis at this level of the respiratory tract. In 
some species, SP-D is also synthesized by epithelial 
cells and/or submucosal glands associated with the 
bronchi and trachea (6). This might explain 
significantly raised sputum levels of SP-D 
especially in TB patients. SP-D has been reported to 
agglutinate bacteria, delay phagocytosis and 
facilitate phagolysosomal fusion (10-12). This 
explains why SP-D was higher in MDR-TB patients 
than DS-TB patients considered for this study.   
The opposing trends of sputum SP-A (reduced 
level) and sputum SP-D (raised level) observed in 
TB patients considered for our study might be 
related to slight differences in their chemical 
composition and functions. SP-A preferentially 
binds monosaccharides and lipid ligands, while SP-
D additionally binds disaccharides, complex 
carbohydrates and anionic phospholipids present 
on cell surfaces (18). This might be explained by 
subtle structural differences between the CRDs of 
trimeric SP-A and SP-D resulting in the flatter and 
more hydrophobic surface of SP-A preferentially 
binding to less polar substrates, while the more 
hydrophilic surface of SP-D displays a higher 
affinity for highly polar targets (24). Moreover, in 
SP-A, the Gly-X-Y repeats in the collagenous region 
are interrupted resulting in a kink (and hence the 
bunch-like structure) and a relatively smaller 
distance to the distal CRD compared to SP-D which 
displays more freedom to bind and aggregate target 
pathogens (25). 
In the case of M. tuberculosis, SP-D has been shown 
to bind mannosylated lipoarabinomannan 
(ManLam) from the Erdman strain (26), while SP-A 
has been shown to bind a wider range of 
mycobacterial targets, including ManLam (from 
virulent and avirulent mycobacterial strains) (27), 
lipomannan (28), a 60-kDa glycoprotein (29), and 
the M. tuberculosis surface glycoprotein Apa (30). 
In addition to their carbohydrate specificities, SP-A 
and SP-D was also reported to differ with respect to 
several other structural features that determine 
their interactions with the innate immune system. 
SP-A forms a bouquet-like 18-mer that associates 
with surfactant lipids and tubular myosin and can 
bind to the C1qR receptor, toll-like receptors TLR2 
and TLR4, the CD91/calreticulin complex, the 
signal inhibitory regulatory protein SIRP-alpha, and 
the unconventional myosin XVIIIA receptor 
SPR210. SP-D, on the other hand, forms a cross-like 
dodecamer (12 chains) that resides in the aqueous 
phase of the alveoli and can bind microfibril-
associated protein 4, CD14, defensins, decorin, C1q, 
TLR2, TLR4, and a 340-kDa glycoprotein of 
unknown function (31). 
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Exploration of surfactant A therapeutic potential is 
proposed by the present authors.  Animal study 
and limited human data show that exogenous 
surfactant decreases DNA synthesis of 
inflammatory mediators (32, 33). Intratracheal 
administration of a surfactant–amikacin mixture to 
rats with Pseudomonas pneumonia showed improved 
anti-inflammatory effects compared with amikacin 
alone (33). There is also evidence that certain 
pharmacologic agents may enhance endogenous 
surfactant levels, although the current data are 
limited. Antenatal steroids accelerate development 
of type 2 pneumocytes and thus increase the 
production of surfactant proteins and enzymes 
necessary for phospholipid synthesis. 
Corticosteroids also induce pulmonary β-receptors, 
which play a role in surfactant release and alveolar 
fluid absorption when stimulated (34). These 
observations suggest the possibility that surfactant 
or its stimulants be used to modulate immune 
responses during inflammatory lung disease like 
tuberculosis, but further studies are necessary. 
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